EVAg

Infectious cell culture supernatant containing SARS-CoV-2, JN.1. Isolated from throat/Nasopharynx and cultured on Calu-3 cells.

Infectious cell culture supernatant containing SARS-CoV-2, JN.1.4. Isolated from throat/Nasopharynx and cultured on Calu-3 cells.

Infectious cell culture supernatant containing SARS-CoV-2, JN.1. Isolated from throat/Nasopharynx and cultured on Calu-3 cells.

Infectious cell culture supernatant containing SARS-CoV-2, JN.1.19. Isolated from throat/Nasopharynx and cultured on Calu-3 cells.

Human monoclonal recombinant IgG1 targeting the S2 domain of SARS-CoV-2 Spike as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the S1 domain of SARS-CoV-2 Spike as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the S1 domain of SARS-CoV-2 Spike domain of the wild type strain, as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the S2 domain of SARS-CoV-2 Spike as determined by ELISA

Human monoclonal recombinant IgG1 targeting the S2 domain of HCoV-OC43 Spike domain, as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the S2 domain of SARS-CoV-2 Spike domain of the wild type strain, as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the RBD domain of SARS-CoV-2 Spike domain of the wild type strain, as determined by ELISA.

SARS-CoV-2 omicron BA.5

Infectious cell culture supernatant containing SARS-CoV-2 (hCoV-19/Netherlands/NH-EMC-1720/2021, Omicron variant, lineage B.1.1.529.

Vial containing RNA of SARS-CoV-2 (hCoV-19/Netherlands/NH-EMC-1720/2021, Omicron variant, lineage B.1.1.529. This strain has been cultivated on Calu-3 cells. . GSAID reference: hCoV-19/Netherlands/NH-RIVM-71084/2021.

Infectious cell culture supernatant of SARS-CoV-2 from The Netherlands

Middle East respiratory Syndrome coronavirus (MERS-CoV) was isolated in June 2012 from a man with acute pneumonia and renal failure.

Serum obtained from rabbits challenged with MERS-CoV.

Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone marrow of MERS-CoV infected dromedaries, MERS-CoV specific VHHs or nanobodies were produced. VHH-83 binds with exceptionally high affinity to the receptor binding domain of the viral spike protein. In vitro, this VHH efficiently blocks virus entry at picomolar concentrations

Serum obtained from dromedary camels immunized with a MVA vaccine expressing the spike protein and challenged with MERS-CoV.

HCAb-83 is a MERS-CoV specific camel/human chimeric heavy chain only antibody (HCAb) - composed of the camel VHH-83 linked to a human Fc domain lacking the CH1 exon Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone marrow of MERS-CoV infected dromedaries, MERS-CoV specific VHHs or nanobodies were produced. VHH-83 binds with exceptionally high affinity to the receptor binding domain of the viral spike protein. In vitro, HCAb-83 efficiently blocks virus entry at picomolar concentrations

Panel consists of (cell-culture) RNA from different coronaviruses (HCoV-Nl63, HCoV-229E, HCoV-OC43, MERS-CoV and SARS-CoV) and is intended for use as control of specificity of molecular assays. This panel contains sufficient RNA for t least 5 experiments. "Disclaimer: Import permit may be needed in your country for SARS-CoV full virus RNA. If yes, please indicate so in your online enquiry". Product for Alphacoronavirus and Betacoronavirus. ------------------ NB: indicated price is only valid for non-profit laboratories. Commercial users will be contacted about pricing.

In this 2-day course the basic principles of routine virus neutralization and ELISA assays will be addressed by a combination of lectures, demonstration and hands-on training. Special attention will be given to quality control and assay validation. Topics include: cell culture, biosafety procedures, preparation of sera and virus stocks, ELISA and microarray formats, different virus neutralization tests using pseudotyped viruses and wildtype viruses, immunofluorescence staining of cells, calculation of titers, assay validation and quality control.